Liakou Christina D, Askiti Varvara, Mitsioni Andromachi, Stefanidis Constantinos J, Theodoridou Maria C, Spoulou Vana I
1st Department of Pediatrics, Infectious Diseases Unit, "Aghia Sophia" Children's Hospital, Athens University School of Medicine, Athens, Greece.
Department of Nephrology, "P. and A. Kyriakou" Children's Hospital, Athens, Greece.
Vaccine. 2014 Mar 10;32(12):1394-7. doi: 10.1016/j.vaccine.2013.11.106. Epub 2014 Jan 30.
Safety and immunogenicity of a booster dose of 7-valent pneumococcal conjugate vaccine (PCV7) were evaluated in 29 patients with idiopathic nephrotic syndrome (INS), who had been primed 12 months earlier with one dose of PCV7. PCV7 was not associated with increased risk of INS relapse (RR=0.77, p=0.8) and serotype-specific antibodies increased in all subjects at 1 month (p<0.01). The quantitative characteristics of immune response and the effect of treatment with mycophenolate mofetil and/or cyclosporine A following booster PCV7 were similar with primary response. Additional PCV7 doses could be safely given in children with INS to increase circulating antibodies above the protective threshold.
在29例特发性肾病综合征（INS）患者中评估了一剂7价肺炎球菌结合疫苗（PCV7）加强剂量的安全性和免疫原性，这些患者在12个月前已接种过一剂PCV7进行基础免疫。PCV7与INS复发风险增加无关（相对危险度=0.77，p=0.8），并且所有受试者在1个月时血清型特异性抗体均增加（p<0.01）。加强接种PCV7后免疫反应的定量特征以及霉酚酸酯和/或环孢素A治疗的效果与初次反应相似。可以安全地给INS患儿额外接种PCV7剂量，以使循环抗体增加到高于保护阈值。
